These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29355526)

  • 1. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome.
    Bosc E; Nastri J; Lefort V; Valli M; Contiguiba F; Pioli R; Furlan M; Bolzani VDS; El Amri C; Reboud-Ravaux M
    Biochem Biophys Res Commun; 2018 Feb; 496(3):961-966. PubMed ID: 29355526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs.
    Adams DJ; Dai M; Pellegrino G; Wagner BK; Stern AM; Shamji AF; Schreiber SL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15115-20. PubMed ID: 22949699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
    Ladi E; Everett C; Stivala CE; Daniels BE; Durk MR; Harris SF; Huestis MP; Purkey HE; Staben ST; Augustin M; Blaesse M; Steinbacher S; Eidenschenk C; Pappu R; Siu M
    J Med Chem; 2019 Aug; 62(15):7032-7041. PubMed ID: 31283222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
    Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
    Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
    Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies.
    Bandoh N; Ogino T; Cho HS; Hur SY; Shen J; Wang X; Kato S; Miyokawa N; Harabuchi Y; Ferrone S
    Tissue Antigens; 2005 Sep; 66(3):185-94. PubMed ID: 16101829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.
    Zou Y; Yan C; Zhang H; Xu J; Zhang D; Huang Z; Zhang Y
    Eur J Med Chem; 2017 Sep; 138():313-319. PubMed ID: 28686911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
    Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
    Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
    Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
    Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening.
    Kasam V; Lee NR; Kim KB; Zhan CG
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3614-7. PubMed ID: 24913713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
    Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
    Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoproteasome in Macaca fascicularis: no age-dependent modification of abundance and activity in the brain and insight into an in silico structural model.
    Bellavista E; Mishto M; Santoro A; Bertoni-Freddari C; Sessions RB; Franceschi C
    Rejuvenation Res; 2008 Feb; 11(1):73-82. PubMed ID: 17985946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation.
    Sun AL; Mu WW; Li YM; Sun YL; Li PX; Liu RM; Yang J; Liu GY
    Molecules; 2021 May; 26(11):. PubMed ID: 34071298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic insights on petrosaspongiolide M inhibitory effects on immunoproteasome and autophagy.
    Monti MC; Margarucci L; Riccio R; Bonfili L; Mozzicafreddo M; Eleuteri AM; Casapullo A
    Biochim Biophys Acta; 2014 Apr; 1844(4):713-21. PubMed ID: 24530967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
    Liu X; Wang Y; Zhang X; Gao Z; Zhang S; Shi P; Zhang X; Song L; Hendrickson H; Zhou D; Zheng G
    Bioorg Med Chem; 2018 Aug; 26(14):3925-3938. PubMed ID: 29925484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation.
    Yan WJ; Wang Q; Yuan CH; Wang F; Ji Y; Dai F; Jin XL; Zhou B
    Free Radic Biol Med; 2016 Aug; 97():109-123. PubMed ID: 27233942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine derived cyclic sulfonamides (sultams): Synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines.
    Lad NP; Kulkarni S; Sharma R; Mascarenhas M; Kulkarni MR; Pandit SS
    Eur J Med Chem; 2017 Jan; 126():870-878. PubMed ID: 27987486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders.
    Zerfas BL; Maresh ME; Trader DJ
    J Med Chem; 2020 Mar; 63(5):1841-1858. PubMed ID: 31670954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS.
    Dechavanne V; Vilbois F; Glez L; Antonsson B
    Protein Expr Purif; 2013 Feb; 87(2):100-10. PubMed ID: 23147206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.